If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms’ Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
